Tonix Pharmaceuticals Holding Corp. SEC filings document a commercial-stage biotechnology company with Nasdaq-listed common stock and programs spanning CNS disorders, immunology, infectious diseases and rare diseases. Recent Form 8-K reports cover Regulation FD disclosures, selected operating and financial results, capital-structure information, commercial arrangements for TONMYA, and clinical or preclinical updates for programs such as TNX-4800, TNX-1700 and TNX-1900.
The company’s proxy and annual meeting filings describe board elections, shareholder voting results, equity incentive plan approvals, executive compensation matters and other governance subjects. Tonix filings also provide formal records of material events, exhibit-based press releases and presentations, risk-related disclosures, registered securities and public-company reporting obligations.
SAENGER BRADLEY reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. reported that Chief Financial Officer Bradley Saenger received two grants of stock options on February 24, 2026, covering 39,012 and 39,011 underlying shares. The options were issued under the company’s Amended and Restated 2020 Stock Incentive Plan.
According to the vesting terms, one-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments of 1/48 each month over the following 36 months. These awards increase the CFO’s directly held derivative securities in the company.
SULLIVAN GREGORY M reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. Chief Medical Officer Gregory M. Sullivan reported receiving two grants of stock options covering 39,012 and 39,011 shares on February 24, 2026. One-third of each option grant vests on the first anniversary of issuance, with the remaining portion vesting monthly over the following 36 months. The options were granted under the company's Amended and Restated 2020 Stock Incentive Plan.
Fogarty Siobhan reported acquisition or exercise transactions in this Form 4 filing.
Tonix Pharmaceuticals Holding Corp. reported that Chief Technology Officer Siobhan Fogarty received two grants of stock options. One option covers 39,012 shares and the other covers 39,011 shares, both recorded as awards with no cash paid per option at grant.
According to the terms, one-third of each option vests on the first anniversary of issuance, and the remaining portion vests in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan, providing long-term, equity-based compensation tied to the company’s share performance.
Tonix Pharmaceuticals Holding Corp. reported that Chief Executive Officer Seth Lederman received two grants of stock options. Each grant is for stock options at an exercise price of $0.00 per share, dated February 24, 2026, and held directly by him.
One option grant covers 134,504 stock options and the other covers 134,503 stock options. According to the filing, one-third of each option vests on the first anniversary of issuance, with the remaining portion vesting in equal monthly installments over the following 36 months. The options were granted under the company’s Amended and Restated 2020 Stock Incentive Plan.
Tonix Pharmaceuticals Holding Corp. released preliminary, unaudited operating results for the quarter and year ended December 31, 2025, along with early views on its financial condition as of January 30, 2026.
The company states that based on current estimates, its cash resources at December 31, 2025 are expected to fund planned operating and capital spending into the first quarter of 2027. Management emphasizes that the figures are preliminary, may change as year-end closing and audit work proceed, and should not be treated as final results. Tonix expects to file its full audited financial statements in its Form 10-K for 2025 on or about March 16, 2026.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of Tonix Pharmaceuticals Holding Corp common stock. Vanguard reports holding 673,605 shares, representing 5.02% of the outstanding common stock as of 12/31/2025, indicating a sizable institutional position.
Vanguard has shared voting power over 79,137 shares and shared dispositive power over all 673,605 shares, with no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Tonix. Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries may report ownership separately.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 854,579 shares of Tonix Pharmaceuticals Holding Corp. common stock, representing 6.7% of the outstanding class as of 12/31/2025. BlackRock reports sole voting power over 845,544 shares and sole dispositive power over 854,579 shares, with no shared voting or dispositive power.
The filing explains that the position reflects securities beneficially owned, or deemed beneficially owned, by certain BlackRock business units, and excludes other disaggregated units. It also notes that various persons have the right to receive dividends or sale proceeds from these shares, but no single person has more than five percent of Tonix Pharmaceuticals Holding Corp.’s outstanding common stock. BlackRock certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Tonix Pharmaceuticals Holding Corp. licensed exclusive worldwide rights to TNX-4900, a small-molecule candidate for chronic neuropathic pain, from Rutgers University. TNX-4900 is a highly selective Sigma-1 receptor antagonist with nanomolar affinity (Ki = 7.5 nM) and more than hundred-fold selectivity over Sigma-2, intended as a non-opioid approach to treating neuropathic pain.
In preclinical models of diabetic and chemotherapy-induced neuropathic pain, TNX-4900 produced significant and durable reductions in pain behaviors after both acute and chronic dosing, without evidence of tolerance or motor impairment. The compound shows high blood-brain barrier penetration and oral bioavailability of approximately 28%. Tonix plans additional pharmacokinetic, formulation and safety studies to potentially support an Investigational New Drug application with the U.S. Food and Drug Administration.
Tonix Pharmaceuticals Holding Corp. reported that the U.S. FDA has cleared its Investigational New Drug application for TNX-102 SL 5.6 mg, enabling clinical development for treating major depressive disorder (MDD) in adults. The company plans a potentially pivotal Phase 2 HORIZON study, a 6-week, randomized, double-blind, placebo-controlled trial of TNX-102 SL as first-line monotherapy in about 360 adults across approximately 30 U.S. sites. The primary goal is to measure change in Montgomery-Asberg Depression Rating Scale-II scores at Week 6, with additional measures of overall clinical impression, anxiety, and sleep disturbance, and enrollment is planned to begin in mid-year 2026.
Tonix Pharmaceuticals (TNXP) is updating its at-the-market common stock offering program under its existing Sales Agreement with A.G.P./Alliance Global Partners. The company is now offering up to an aggregate of $400,000,000 of its common stock under this program.
Under the prior prospectus, Tonix had registered up to $150,000,000 and sold 3,882,223 shares of common stock for an aggregate purchase price of $103.1 million. Following this prospectus supplement dated November 21, 2025, Tonix may sell up to an additional $296.9 million of common stock under the Sales Agreement.